KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Debt Repayments (2021 - 2025)

Alnylam Pharmaceuticals posted quarterly Long-Term Debt Repayments of $52.3 million for Q4 2025, down 95.29% on a QoQ basis from $1.1 billion in Q3 2025.

Alnylam Pharmaceuticals (ALNY) has 3 years of Long-Term Debt Repayments data on file, last reported at $52.3 million in Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Debt Repayments changed N/A year-over-year to $52.3 million; the trailing twelve-month figure through Dec 2025 stood at $1.2 billion (up 213.48% YoY), and the FY2025 full-year result was $1.2 billion, changed N/A from the prior year.
  • Long-Term Debt Repayments for Q4 2025 stood at $52.3 million, down from $1.1 billion in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $1.1 billion in Q3 2025 and bottomed at -$1.5 billion in Q4 2022.
  • The 3-year median for Long-Term Debt Repayments is $276.2 million (2021), against an average of $34.5 million.
  • Peak annual rise in Long-Term Debt Repayments reached 404.84% in 2022, while the deepest fall reached 404.84% in 2022.
  • A 3-year view of Long-Term Debt Repayments shows it stood at $500.0 million in 2021, then plunged by 404.84% to -$1.5 billion in 2022, then jumped by 103.43% to $52.3 million in 2025.
  • The last three Long-Term Debt Repayments figures came in at $52.3 million (Q4 2025), $1.1 billion (Q3 2025), and -$1.5 billion (Q4 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Revolution Medicines 32.39 Bn 32.39 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 52.30 Mn
Dec 31, 2025 52.30 Mn
Sep 30, 2025 1.11 Bn
Sep 30, 2025 1.11 Bn
Dec 31, 2022 -1.52 Bn
Dec 31, 2022 -1.52 Bn
Dec 31, 2021 500.00 Mn
Dec 31, 2021 500.00 Mn